Open Nav

Orum Therapeutics Inc

  • SJ Lee, Orum Therapeutics

Introduction to potential Series B investors

  • Date:Wednesday, October 17
  • Time:9:45 AM - 10:00 AM
  • Room:Elizabethan D
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:Orum Therapeutics is a private biotech developing a new class of therapeutic antibodies to target previously undruggable proteins that are involved in aggressive cancers and severe genetic diseases. Orum's unique cell-penetrating antibody platform is easily adaptable to target specific cell types and inhibit different intracellular drug targets, without chemical modification. The company has a pipeline of preclinical therapeutic candidates, of which the most advanced targets oncogenic RAS.
  • Company Website:
  • Company HQ City:Daejeon
  • Company HQ Country:Korea - South Korea
  • Main Therapeutic Focus:Multiple Therapeutics
  • Lead Product in Development : Cell-Penetrating Antibodies to Oncogenic RAS
  • Development Phase of Primary Product:Discovery
  • Total Amount Raised to Date, In All Rounds:$9M
SJ Lee
Orum Therapeutics